Physician profile
Paridhi Mathur
NPI 1972024768
$1,815.01
in general payments reported to CMS, 2019-2025
28 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.93 · 2020: $50.55 · 2021: $218 · 2022: $259 · 2023: $194 · 2024: $500 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.19 | 2023-2025 | |
| Novo Nordisk INC | $160.75 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $160.35 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $134.76 | 2021-2025 | Jardiance, Trulicity, Mounjaro |
| Glaxosmithkline, LLC. | $104.25 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Abiomed | $91.17 | 2024-2025 | Impella |
| Exact Sciences Corporation | $80.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.00 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Phathom Pharmaceuticals, INC. | $64.89 | 2024-2025 | Voquezna |
| Pfizer INC. | $56.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $51.38 | 2021-2025 | Breztri |
| Amarin Pharma, INC. | $47.83 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $40.73 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $34.68 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $33.58 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $33.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.82 | 2021-2023 | |
| Janssen Biotech, INC. | $23.62 | 2025 | Tremfya |
| Melinta Therapeutics, LLC | $21.17 | 2020 | |
| Si-Bone, INC. | $19.25 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.84 | 2020 | |
| Ani Pharmaceuticals, INC. | $16.49 | 2024 | Purified Cortrophin Gel |
| Hologic Sales and Service, LLC | $16.45 | 2021 | |
| Dynavax Technologies Corporation | $14.96 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.92 | 2024 | Caplyta |
| Abbott Laboratories | $14.92 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $14.20 | 2021 | |
| Inogen, INC. | $7.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paridhi Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.